Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2015, Article ID 568702, 6 pages
http://dx.doi.org/10.1155/2015/568702
Research Article

High Prevalence of Cardiovascular Disease in End-Stage Kidney Disease Patients Ongoing Hemodialysis in Peru: Why Should We Care About It?

1University of Rochester Medical Center, 601 Elmwood Avenue, Box MED, Rochester, NY 14642, USA
2Facultad de Medicina de San Fernando, Universidad Nacional Mayor de San Marcos (UNMSM), Lima, Peru

Received 15 May 2015; Revised 8 July 2015; Accepted 8 July 2015

Academic Editor: Alessandro Amore

Copyright © 2015 Katia Bravo-Jaimes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Schieppati and G. Remuzzi, “Chronic renal diseases as a public health problem: epidemiology, social, and economic implications,” Kidney International, Supplement, vol. 68, no. 98, pp. S7–S10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. U.S.RDS, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
  3. A. M. Cusumano, M. C. G. Bedat, G. García-García et al., “Latin American dialysis and renal transplant registry: 2008 report (data 2006),” Clinical Nephrology, vol. 74, supplement 1, pp. S3–S8, 2010. View at Google Scholar · View at Scopus
  4. I. Montalvo-Roel, Estado Situacional de los Pacientes con Enfermedad Renal Crónica y la Aplicación de Diálisis como Tratamiento en el Perú, Departamento de Investigaciones y Documentación Parlamentaria (DIDP), 2012.
  5. A. S. Levey, J. A. Beto, B. E. Coronado et al., “Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease,” The American Journal of Kidney Diseases, vol. 32, no. 5, pp. 853–906, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. A. K. Cheung, M. J. Sarnak, G. Yan et al., “Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients,” Kidney International, vol. 58, no. 1, pp. 353–362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. K/DOQI Workgroup, “K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients,” American Journal of Kidney Diseases, vol. 45, no. 4, supplement 3, pp. S1–S153, 2005. View at Publisher · View at Google Scholar
  8. P. S. Parfrey and R. N. Foley, “The clinical epidemiology of cardiac disease in chronic renal failure,” Journal of the American Society of Nephrology, vol. 10, no. 7, pp. 1606–1615, 1999. View at Google Scholar · View at Scopus
  9. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” American Journal of Kidney Diseases, vol. 32, no. 5, supplement 3, pp. S112–S119, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Sarnak and A. S. Levey, “Cardiovascular disease and chronic renal disease: a new paradigm,” American Journal of Kidney Diseases, vol. 35, no. 4, pp. S117–S131, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Kundhal and C. E. Lok, “Clinical epidemiology of cardiovascular disease in chronic kidney disease,” Nephron: Clinical Practice, vol. 101, no. 2, pp. c47–c52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Portolés, J. M. López-Gómez, P. Aljama, and A. M. Tato, “Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR Study),” Nefrologia, vol. 25, no. 3, pp. 297–306, 2005. View at Google Scholar · View at Scopus
  13. S. H. Park, C. Shub, T. P. Nobrega, K. R. Bailey, and J. B. Seward, “Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography,” Journal of the American Society of Echocardiography, vol. 9, no. 2, pp. 119–128, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. K. G. Alberti, P. Zimmet, and J. Shaw, “Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Google Scholar
  15. H. Rimington, Echocardiography: A Practical Guide for Reporting, Informa Healthcare, 2nd edition, 2007.
  16. WHO, “Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System,” Tech. Rep. WHO/NMH/NHD/MNM/111, World Health Organization, Geneva, Switzerland, 2011. View at Google Scholar
  17. G. Moretta, A. J. Locatelli, L. Gadola et al., “Rio de La Plata study: a multicenter, cross-sectional study on cardiovascular risk factors and heart failure prevalence in peritoneal dialysis patients in Argentina and Uruguay,” Kidney International. Supplement, no. 108, pp. S159–S164, 2008. View at Google Scholar · View at Scopus
  18. M. E. Sanhueza Villanueva, A. Cotera, L. Elgueta et al., “Assessment and follow up of diabetic patients in hemodialysis,” Revista Medica de Chile, vol. 136, no. 3, pp. 279–286, 2008. View at Google Scholar · View at Scopus
  19. R. J. Glassock, R. Pecoits-Filho, and S. H. Barberato, “Left ventricular mass in chronic kidney disease and ESRD,” Clinical Journal of the American Society of Nephrology, vol. 4, supplement 1, pp. S79–S91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Quiroga, M. Villaverde, S. Abad, A. Vega, J. Reque, and J. M. López-Gómez, “Diastolic dysfunction and high levels of new cardiac biomarkers as risk factors for cardiovascular events and mortality in hemodialysis patients,” Blood Purification, vol. 36, no. 2, pp. 98–106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. F. U. Dzgoeva, T. M. Gatagonova, Z. K. Kadzaeva et al., “Diastolic dysfunction in different types of left ventricular hypertrophy in patients with end-stage renal failure: impact of long-term erythropoietin therapy,” Terapevticheskii Arkhiv, vol. 85, no. 6, pp. 44–50, 2013. View at Google Scholar · View at Scopus
  22. R. Pecoits-Filho, S. Bucharles, and S. H. Barberato, “Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment,” Seminars in Dialysis, vol. 25, no. 1, pp. 35–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. B. C. Fellström, A. G. Jardine, R. E. Schmieder et al., “Rosuvastatin and cardiovascular events in patients undergoing hemodialysis,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1395–1407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. W. Nemerovski, J. Lekura, M. Cefaretti, P. T. Mehta, and C. L. Moore, “Safety and efficacy of statins in patients with end-stage renal disease,” Annals of Pharmacotherapy, vol. 47, no. 10, pp. 1321–1329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Bevc, A. Potočnik, and R. Hojs, “Lipids, waist circumference and body mass index in haemodialysis patients,” Journal of International Medical Research, vol. 39, no. 3, pp. 1063–1074, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Al Saran, S. Elsayed, A. Sabry, and M. Hamada, “Obesity and metabolic syndrome in hemodialysis patients: single center experience,” Saudi Journal of Kidney Diseases and Transplantation, vol. 22, no. 6, pp. 1193–1198, 2011. View at Google Scholar
  27. M. Jalalzadeh, R. Mohammadi, F. Mirzamohammadi, and M. H. Ghadiani, “Prevalence of metabolic syndrome in a hemodialysis population,” Iranian Journal of Kidney Diseases, vol. 5, no. 4, pp. 248–254, 2011. View at Google Scholar · View at Scopus
  28. A. I. Q. Alfonso, R. F. Gallegos, R. F. Castillo, F. J. G. Jimenez, M. C. G. Rios, and I. G. Garcia, “Study of the metabolic syndrome and obesity in hemodialysis patients,” Nutrición Hospitalaria, vol. 31, no. 1, pp. 286–291, 2015. View at Google Scholar
  29. A. P. de José, Ú. Verdalles-Guzmán, S. Abad et al., “Metabolic syndrome is associated with cardiovascular events in hemodialysis,” Nefrologia, vol. 34, no. 1, pp. 69–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. C.-C. Wu, H.-H. Liou, P.-F. Su et al., “Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients,” Nephrology Dialysis Transplantation, vol. 26, no. 11, pp. 3689–3695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Kawaguchi, L. Tong, B. M. Robinson et al., “C-reactive protein and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS),” Nephron—Clinical Practice, vol. 117, no. 2, pp. c167–c178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. T.-R. Valdivia-Mazeyra, L.-Q. Cesar, and M. Teresa, “Asymptomatic cerebrovascular lesions and their relationship to vascular risk factors in patients with end stage renal disease on hemodialysis program,” Revista de la Sociedad Peruana de Medicina Interna, vol. 25, no. 4, pp. 163–170, 2012. View at Google Scholar
  34. J. Zimmermann, S. Herrlinger, A. Pruy, T. Metzger, and C. Wanner, “Inflammation enhances cardiovascular risk and mortality in hemodialysis patients,” Kidney International, vol. 55, no. 2, pp. 648–658, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Finelli, J. T. Miller, J. I. Tokars, M. J. Alter, and M. J. Arduino, “National surveillance of dialysis-associated diseases in the United States, 2002,” Seminars in Dialysis, vol. 18, no. 1, pp. 52–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Di Napoli, P. Pezzotti, D. Di Lallo, N. Petrosillo, C. Trivelloni, and S. Di Giulio, “Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region,” American Journal of Kidney Diseases, vol. 48, no. 4, pp. 629–637, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. A.-M. Courouce, F. Bouchardeau, P. Chauveau et al., “Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays),” Nephrology Dialysis Transplantation, vol. 10, no. 2, pp. 234–239, 1995. View at Google Scholar · View at Scopus
  38. B. Othman and F. Monem, “Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria,” Infection, vol. 29, no. 5, pp. 262–265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Covic, L. Iancu, C. Apetrei et al., “Hepatitis virus infection in haemodialysis patients from Moldavia,” Nephrology Dialysis Transplantation, vol. 14, no. 1, pp. 40–45, 1999. View at Publisher · View at Google Scholar · View at Scopus